A report released today by Aegis about Mediwound Ltd (NASDAQ:MDWD) raises the target price to $11.00
- Updated: November 28, 2016
Mediwound Ltd (NASDAQ:MDWD) had its stock price target increased to $11.00 by Aegis in a report released 11/28/2016. The new stock price target indicates a potential upside of 1.10% from the company's last stock close price.
Yesterday Mediwound Ltd (NASDAQ:MDWD) traded 2.68% higher at $5.25. The company’s 50-day moving average is $6.15 and its 200-day moving average is $7.31. The last stock close price is down -26.30% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 23,550 shares of the stock were exchanged, up from an average trading volume of 19,592
See Chart Below
Mediwound Ltd has a 52 week low of $5.00 and a 52 week high of $10.47 The company’s market cap is currently $0.
In addition to Aegis reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $15.00 with 3 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Mediwound Ltd (NASDAQ:MDWD)
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company's proteolytic enzyme technology. NexoBrid is a topically-applied product that removes eschar in approximately four hours without harming the surrounding healthy tissues. The Company offers NexoBrid in Europe and Israel. NexoBrid has been investigated in over 550 patients across approximately 15 countries and over four continents in approximately six completed Phase II and Phase III clinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.